AstraZeneca Pharma India Ltd.

NSE: ASTRAZEN | BSE: 506820 | ISIN: INE203A01020 |Industry: Pharmaceuticals
|Expensive Performer

3180.85
4.74%
WHO chief, Mandaviya talk Covaxin, resuming Covishield supply to COVAX
WHO chief, Mandaviya talk Covaxin, resuming Covishield supply to COVAX
Business Standard
WHO chief Tedros Adhanom Ghebreyesus discussed the issue of the emergency use listing of Bharat Biotech's COVID-19 vaccine Covaxin and resumption of supplies of the Serum Institute of India-manufactured AstraZeneca vaccine to the COVAX facility among other topics during a telephonic conversation with Health Minister Mansukh Mandaviya. Had a call with @mansukhmandviya, India's Health Minister, to discuss #India's ongoing #COVID19 vaccination programme; the need for a global pandemic agreement; digital health; & traditional medicine. We welcome India's support to strengthen WHO, incl. via flexible, sustainable financing, Ghebreyesus tweeted on Tuesday. The WHO Director-General said that he also discussed with Mandaviya vaccine equity issues: the resumption of SII/AstraZeneca vaccine supplies to #COVAX; the Covaxin Emergency Use Listing process; and technology and license sharing through C-TAP. COVID-19 Technology Access Pool (C-TAP) was launched in May last year for facilitating...
default
Recommended
More from AstraZeneca Pharma India Ltd.